IDEAYA Biosciences (IDYA) Projected to Post Earnings on Monday

IDEAYA Biosciences (NASDAQ:IDYA) is anticipated to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.9888) per share and revenue of $5.0380 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.09. The firm had revenue of $10.88 million during the quarter, compared to analyst estimates of $5.95 million. The firm’s revenue was up 55.7% compared to the same quarter last year. During the same period last year, the business earned ($1.49) EPS. On average, analysts expect IDEAYA Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Price Performance

Shares of NASDAQ:IDYA opened at $28.19 on Monday. The firm’s 50 day moving average price is $32.20 and its 200 day moving average price is $32.96. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -21.52 and a beta of -0.04. IDEAYA Biosciences has a fifty-two week low of $16.82 and a fifty-two week high of $39.28.

Analyst Ratings Changes

Several analysts recently weighed in on IDYA shares. Truist Financial set a $65.00 target price on shares of IDEAYA Biosciences in a report on Monday, April 13th. Guggenheim raised their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Wall Street Zen raised shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. The Goldman Sachs Group raised their price objective on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Finally, Citigroup raised their price objective on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.44.

Insiders Place Their Bets

In related news, Director Jeffrey Stein acquired 50,000 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the acquisition, the director owned 54,281 shares in the company, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.50% of the company’s stock.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDYA. GSK plc acquired a new stake in IDEAYA Biosciences during the fourth quarter worth approximately $46,093,000. State Street Corp increased its holdings in shares of IDEAYA Biosciences by 27.6% in the 4th quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after acquiring an additional 893,707 shares during the period. Janus Henderson Group PLC increased its holdings in shares of IDEAYA Biosciences by 11.8% in the 4th quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock valued at $248,344,000 after acquiring an additional 758,117 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of IDEAYA Biosciences by 43.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,770,866 shares of the company’s stock valued at $61,219,000 after acquiring an additional 537,753 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of IDEAYA Biosciences by 88.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 938,857 shares of the company’s stock valued at $32,456,000 after acquiring an additional 441,809 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.